Luxury Brands Are Getting Hit by a Vibe Shift
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 27 2025
0mins
Source: WSJ
Luxury Industry Sales Slump: Bernard Arnault, owner of LVMH, believes the current sales decline in the luxury sector is temporary and will soon recover.
Investment in LVMH: Arnault has invested over $1 billion of his own money into LVMH shares this year, suggesting confidence in the company's future despite a 20% drop in stock value.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UBS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UBS
Wall Street analysts forecast UBS stock price to rise
11 Analyst Rating
7 Buy
2 Hold
2 Sell
Moderate Buy
Current: 39.740
Low
39.12
Averages
52.09
High
71.73
Current: 39.740
Low
39.12
Averages
52.09
High
71.73
About UBS
UBS Group AG is a Switzerland-based holding company and conducts its operations through UBS AG and its subsidiaries. The company operates as a wealth manager with focused asset management and investment banking capabilities and a capital-light and cash-generative business model. The Company comprises four business divisions: Global Wealth Management, which provides tailored advice and solutions to its clients around the globe; Personal & Corporate Banking division provides comprehensive financial products and services to private, corporate and institutional clients in Switzerland; Asset Management division offers investment capabilities and styles across all traditional and alternative asset classes, as well as advisory support to institutions; Investment Bank provides investment advice, financial solutions and capital markets access to institutional, corporate and wealth management clients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intel's Stake Buyback in Ireland Fuels Stock Surge
- Significant Stock Surge: Intel's shares rose nearly 17% over the past week, reflecting strong market confidence in its acquisition strategy and signaling investor optimism about the company's future profitability.
- Major Strategic Acquisition: Intel has agreed to repurchase a 49% stake in its Fab 34 facility in Ireland from Apollo Global Management for $14.2 billion, which produces Xeon 6 and Core Ultra processors, expected to boost per-share profits by 2027.
- Enhanced Market Confidence: Analysts widely view this acquisition as a sign of Intel's improving financial profile and its potential to attract new foundry customers, further solidifying its leadership in the semiconductor market.
- AI-Driven Expansion Plans: The Fab 34 facility is crucial to Intel's AI-driven expansion, and management's decision to acquire it outright reflects confidence in semiconductor manufacturing prospects, leading investors to anticipate further stock price appreciation.
See More
Intel Repurchases Key Chip Facility Stake, Boosting AI Prospects
- Stake Repurchase: Intel has reached an agreement with Apollo Global Management to repurchase a 49% stake in its Fab 34 facility in Ireland for $14.2 billion, which produces Xeon 6 and Core Ultra processors, expected to boost per-share profits by 2027, reflecting the company's confidence in its future profitability.
- Stock Surge: Following this announcement, Intel's shares rose nearly 17% over the past week, indicating market optimism regarding its strengthened foundry network and AI prospects, further solidifying its leadership position in the semiconductor industry.
- Analyst Optimism: UBS analysts suggest that Intel's buyback indicates expectations of gaining new foundry customers, while J.Gold Associates analysts note that the market is purchasing Intel products at scale, demonstrating robust market demand.
- Strategic Importance: The Fab 34 facility is central to Intel's AI-driven expansion plans, and the management's acquisition decision not only reflects confidence in manufacturing prospects but may also lead Wall Street to raise earnings forecasts for Intel, further boosting investor confidence.
See More
SSR Mining Shares Surge 19.9% Driven by Strategic Moves
- Significant Stock Surge: SSR Mining's shares rose by 19.9% in the week ending Friday, signaling strong market interest and boosting shareholder confidence amid ongoing gold price fluctuations.
- Strategic Asset Sale: The company signed a definitive agreement to sell its 80% stake in a Turkish gold mine for $1.5 billion, significantly derisking its operations and allowing a sharper focus on core business in the Americas.
- Share Buyback Approval: SSR Mining received approval from the Toronto Stock Exchange to repurchase about 10% of its outstanding common shares, a move that not only enhances earnings per share but also reflects the company's confidence in its intrinsic value.
- Analyst Rating Upgrade: An analyst from UBS raised the price target on SSR Mining while maintaining a buy rating, which, combined with other positive updates, further propelled the stock price and reinforced investor confidence in gold exposure.
See More
SSR Mining Shares Surge 19.9% Amid Strategic Moves
- Stock Price Surge: SSR Mining's shares rose by 19.9% in the week ending Friday, driven not only by rising gold prices but also by the company's definitive agreement to sell its 80% stake in a Turkish gold mine for $1.5 billion, which derisks operations and boosts investor confidence.
- Share Buyback Plan: The company received approval from the Toronto Stock Exchange to repurchase approximately 10% of its outstanding common shares, a move aimed at enhancing earnings per share and increasing shareholder value, further solidifying market confidence in its stock.
- Analyst Rating Upgrade: An analyst at UBS raised the price target for SSR Mining this week while maintaining a buy rating, indicating a positive outlook for the company's future performance, which may attract more investor interest.
- Market Environment Impact: Despite gold's correlation with the equity market, investors are eager to see gold prices decouple from other asset classes, and SSR Mining's performance offers a solid opportunity for those seeking safe-haven assets, especially amid increasing market volatility.
See More
UBS Announces 53 Advisors Named to 2026 Barron's Top 1500 List
- Advisor Recognition: UBS has announced that 53 financial advisors from its Southeast region have been named to the 2026 Barron's Top 1500 Financial Advisors list, highlighting the firm's excellence and recognition in wealth management.
- Leadership Endorsement: Regional Director Julie Fox emphasized that the expertise and care these advisors provide to clients set them apart, further enhancing UBS's brand image in the competitive financial services landscape.
- Rigorous Selection Criteria: The Barron's list is compiled based on various criteria, including revenue generated for the firm, assets under management, quality of practice, and regulatory record, ensuring the list's authority and fairness.
- Global Wealth Management Leader: As a leading global wealth manager, UBS manages $6.1 trillion in invested assets and remains committed to helping clients achieve their financial goals through personalized advice and solutions.
See More
UBS Initiates Neutral Coverage on Jasper Therapeutics with $1.50 Target
- Coverage Initiation: UBS initiated coverage of Jasper Therapeutics (NASDAQ:JSPR) on March 23, 2026, with a Neutral rating and a $1.50 price target, indicating a cautious outlook due to competitive pressures that may limit upside potential.
- Clinical Data Update: On January 8, 2026, Jasper reported updated data for briquilimab, revealing that 67% of patients achieved a complete response at 12 weeks, while 83% responded by week 3 after the initial dose, highlighting the therapy's promise in chronic spontaneous urticaria (CSU).
- Future Research Plans: The company plans to initiate a Phase 2b study for CSU in the second half of 2026, with BEACON and open-label extension data supporting dose selection, demonstrating positive progress in clinical development.
- Investment Outlook Analysis: While Jasper is viewed as a potential investment, UBS noted that certain AI stocks offer greater upside potential and lower downside risk, reflecting a shift in market preference towards more attractive investment options in the biotech sector.
See More
Intel's Stake Buyback in Ireland Fuels Stock Surge
- Significant Stock Surge: Intel's shares rose nearly 17% over the past week, reflecting strong market confidence in its acquisition strategy and signaling investor optimism about the company's future profitability.
- Major Strategic Acquisition: Intel has agreed to repurchase a 49% stake in its Fab 34 facility in Ireland from Apollo Global Management for $14.2 billion, which produces Xeon 6 and Core Ultra processors, expected to boost per-share profits by 2027.
- Enhanced Market Confidence: Analysts widely view this acquisition as a sign of Intel's improving financial profile and its potential to attract new foundry customers, further solidifying its leadership in the semiconductor market.
- AI-Driven Expansion Plans: The Fab 34 facility is crucial to Intel's AI-driven expansion, and management's decision to acquire it outright reflects confidence in semiconductor manufacturing prospects, leading investors to anticipate further stock price appreciation.
See More
Intel Repurchases Key Chip Facility Stake, Boosting AI Prospects
- Stake Repurchase: Intel has reached an agreement with Apollo Global Management to repurchase a 49% stake in its Fab 34 facility in Ireland for $14.2 billion, which produces Xeon 6 and Core Ultra processors, expected to boost per-share profits by 2027, reflecting the company's confidence in its future profitability.
- Stock Surge: Following this announcement, Intel's shares rose nearly 17% over the past week, indicating market optimism regarding its strengthened foundry network and AI prospects, further solidifying its leadership position in the semiconductor industry.
- Analyst Optimism: UBS analysts suggest that Intel's buyback indicates expectations of gaining new foundry customers, while J.Gold Associates analysts note that the market is purchasing Intel products at scale, demonstrating robust market demand.
- Strategic Importance: The Fab 34 facility is central to Intel's AI-driven expansion plans, and the management's acquisition decision not only reflects confidence in manufacturing prospects but may also lead Wall Street to raise earnings forecasts for Intel, further boosting investor confidence.
See More
SSR Mining Shares Surge 19.9% Driven by Strategic Moves
- Significant Stock Surge: SSR Mining's shares rose by 19.9% in the week ending Friday, signaling strong market interest and boosting shareholder confidence amid ongoing gold price fluctuations.
- Strategic Asset Sale: The company signed a definitive agreement to sell its 80% stake in a Turkish gold mine for $1.5 billion, significantly derisking its operations and allowing a sharper focus on core business in the Americas.
- Share Buyback Approval: SSR Mining received approval from the Toronto Stock Exchange to repurchase about 10% of its outstanding common shares, a move that not only enhances earnings per share but also reflects the company's confidence in its intrinsic value.
- Analyst Rating Upgrade: An analyst from UBS raised the price target on SSR Mining while maintaining a buy rating, which, combined with other positive updates, further propelled the stock price and reinforced investor confidence in gold exposure.
See More
SSR Mining Shares Surge 19.9% Amid Strategic Moves
- Stock Price Surge: SSR Mining's shares rose by 19.9% in the week ending Friday, driven not only by rising gold prices but also by the company's definitive agreement to sell its 80% stake in a Turkish gold mine for $1.5 billion, which derisks operations and boosts investor confidence.
- Share Buyback Plan: The company received approval from the Toronto Stock Exchange to repurchase approximately 10% of its outstanding common shares, a move aimed at enhancing earnings per share and increasing shareholder value, further solidifying market confidence in its stock.
- Analyst Rating Upgrade: An analyst at UBS raised the price target for SSR Mining this week while maintaining a buy rating, indicating a positive outlook for the company's future performance, which may attract more investor interest.
- Market Environment Impact: Despite gold's correlation with the equity market, investors are eager to see gold prices decouple from other asset classes, and SSR Mining's performance offers a solid opportunity for those seeking safe-haven assets, especially amid increasing market volatility.
See More
UBS Announces 53 Advisors Named to 2026 Barron's Top 1500 List
- Advisor Recognition: UBS has announced that 53 financial advisors from its Southeast region have been named to the 2026 Barron's Top 1500 Financial Advisors list, highlighting the firm's excellence and recognition in wealth management.
- Leadership Endorsement: Regional Director Julie Fox emphasized that the expertise and care these advisors provide to clients set them apart, further enhancing UBS's brand image in the competitive financial services landscape.
- Rigorous Selection Criteria: The Barron's list is compiled based on various criteria, including revenue generated for the firm, assets under management, quality of practice, and regulatory record, ensuring the list's authority and fairness.
- Global Wealth Management Leader: As a leading global wealth manager, UBS manages $6.1 trillion in invested assets and remains committed to helping clients achieve their financial goals through personalized advice and solutions.
See More
UBS Initiates Neutral Coverage on Jasper Therapeutics with $1.50 Target
- Coverage Initiation: UBS initiated coverage of Jasper Therapeutics (NASDAQ:JSPR) on March 23, 2026, with a Neutral rating and a $1.50 price target, indicating a cautious outlook due to competitive pressures that may limit upside potential.
- Clinical Data Update: On January 8, 2026, Jasper reported updated data for briquilimab, revealing that 67% of patients achieved a complete response at 12 weeks, while 83% responded by week 3 after the initial dose, highlighting the therapy's promise in chronic spontaneous urticaria (CSU).
- Future Research Plans: The company plans to initiate a Phase 2b study for CSU in the second half of 2026, with BEACON and open-label extension data supporting dose selection, demonstrating positive progress in clinical development.
- Investment Outlook Analysis: While Jasper is viewed as a potential investment, UBS noted that certain AI stocks offer greater upside potential and lower downside risk, reflecting a shift in market preference towards more attractive investment options in the biotech sector.
See More
